An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Volunteers
Health Professionals
What is the purpose of this trial?
This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR NHL) and a Dose Expansion Phase (Part B) of CA-4948 in patients with RR NHL with and without myeloid differentiation primary response 88 (MYD88) mutations. During Part B, patients will be enrolled regardless of MYD88 mutation status.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alexis Walker
- Alfredo Axtmayer
- Alison Johnson
- Andrea Brennan
- Antonio Omuro, MD
- Catherine Wei, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Francine Foss, MD
- Harold Tara Jr, MD
- Iris Isufi, MD
- James Vredenburgh, MD
- Jean Vollmer
- Justin Persico, MD
- Kaitlin Brown
- Karishma Mehra, MBBS
- Kathleen Fenn, MD
- Kelsey Martin, MD
- Larisa Fleysher
- Madeline Santiago
- Mary Michele Barden, MD
- Matthew Dodd, PA-C
- Michael Cohenuram, MD
- Neal Fischbach, MD
- Nicholas Blondin, MD
- Pawan Karanam, MD
- Renee Moye
- Scott Huntington, MD, MPH, MSc
- Shalin Kothari, MD
- Stuart Seropian, MD
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tarsheen Sethi, MD, MSc
- Vanessa Nevins, PA-C
- Vidya Kesavan
- Last Updated04/16/2024
- Study HIC#2000022049